CD8A and neoplasm: Collectively, these data identify SOCS1 as a target that, upon CRISPR/Cas9-mediated inactivation, enhances the ability of TILs to expand under manufacturing conditions and to drive the infiltration and accumulation of tumor-specific CD8+ T cells within solid tumors in an in vivo setting.